Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk
- PMID: 20360147
- DOI: 10.1093/mutage/geq015
Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk
Abstract
Matrix metalloproteinase (MMP) 2, MMP7 and MMP9 are important members of the MMP family. Four polymorphisms in the promoter region of these MMPs, which are MMP2 -1306 C>T, MMP2 -735 C>T, MMP7 -181 A>G and MMP9 -1562 C>T, have been reported to be functional and may contribute to genetic susceptibility to cancers. However, the associations between these polymorphisms and cancer risk remain inconclusive due to conflicting results from different case-control studies. To better evaluate the role of these polymorphisms in cancer development, we conducted a meta-analysis that included 51 studies, with more than 40,000 subjects. The results showed that under dominant genetic model, MMP2 -1306 T was associated with lower susceptibility to lung cancer [odds ratio (OR) = 0.50, 95% confidence interval (CI) 0.43-0.59, P(heterogeneity) = 0.147, I(2) = 44.1%], head and neck cancer (OR = 0.53, 95% CI 0.41-0.69, P(heterogeneity) = 0.974, I(2) = 0.0%) and oesophageal cancer (OR = 0.67, 95% CI 0.55-0.80, P(heterogeneity) = 0.593, I(2) = 0.0%); MMP2-735T was associated with lower risk in lung cancer (OR = 0.65, 95%CI 0.53-0.79, P(heterogeneity) = 0.42, I(2) = 0.0%) and oesophageal cancer (OR = 0.84, 95% CI 0.70-0.99, P(heterogeneity) = 0.206, I(2) = 37.4%); MMP7 -181 AG and GG genotype carriers had an increased gastric cancer risk (OR = 1.90, 95% CI 1.43-2.51, P(heterogeneity) = 0.992, I(2) = 0.0%) and MMP9 -1562 C>T was not associated with cancer risk in the whole group analysis (OR = 0.99, 95% CI 0.91-1.08, P(heterogeneity) = 0.419, I(2) = 3.0%) and subgroup analyses. In all, our meta-analysis suggests that MMP2 -1306 C>T, MMP2 -735 C>T and MMP7 -181 A>G may play allele-specific roles in cancer development, while MMP9 -1562 C>T may not be a major risk factor for most cancer types. Large case-control studies should be performed to clarify the possible roles of these four polymorphisms in different kinds of cancer in more detail.
Similar articles
-
Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis.Gene. 2013 Mar 15;517(1):65-71. doi: 10.1016/j.gene.2012.12.085. Epub 2013 Jan 9. Gene. 2013. PMID: 23313298
-
Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies.Mutagenesis. 2010 Jan;25(1):41-8. doi: 10.1093/mutage/gep041. Epub 2009 Oct 20. Mutagenesis. 2010. PMID: 19843588
-
Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma.Hum Mutat. 2007 Nov;28(11):1091-7. doi: 10.1002/humu.20570. Hum Mutat. 2007. PMID: 17607721
-
Matrix metalloproteinase (MMP) -2, -7 and -9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population - A case-control study and a mini review.Gene. 2016 Sep 1;589(1):81-89. doi: 10.1016/j.gene.2016.05.028. Epub 2016 May 21. Gene. 2016. PMID: 27222481 Review.
-
FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.Eur J Cancer. 2010 Dec;46(18):3332-8. doi: 10.1016/j.ejca.2010.06.017. Epub 2010 Jul 16. Eur J Cancer. 2010. PMID: 20638838 Review.
Cited by
-
Synergistic effects of TIMP2-418G/C and MMP9-1562C/T variants on the male infertility risk.Mol Biol Rep. 2019 Feb;46(1):861-866. doi: 10.1007/s11033-018-4541-9. Epub 2018 Dec 4. Mol Biol Rep. 2019. PMID: 30515695
-
Epidemiological Evidence Between Variants in Matrix Metalloproteinases-2, -7, and -9 and Cancer Risk.Front Oncol. 2022 Apr 28;12:856831. doi: 10.3389/fonc.2022.856831. eCollection 2022. Front Oncol. 2022. PMID: 35574300 Free PMC article.
-
The influence of matrix metalloproteinase-2, -9, and -12 promoter polymorphisms on Iranian patients with oesophageal squamous cell carcinoma.Contemp Oncol (Pozn). 2015;19(4):300-5. doi: 10.5114/wo.2015.48569. Epub 2015 Aug 13. Contemp Oncol (Pozn). 2015. PMID: 26557778 Free PMC article.
-
The association of matrix metalloproteinase-9 promoter polymorphisms with gastric cancer risk: a meta-analysis.Oncotarget. 2017 Sep 15;8(58):99024-99032. doi: 10.18632/oncotarget.20931. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228747 Free PMC article.
-
Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction.PLoS One. 2013;8(3):e59157. doi: 10.1371/journal.pone.0059157. Epub 2013 Mar 19. PLoS One. 2013. PMID: 23527119 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous